MCLEAN, Virginia and BUDAPEST, Hungary, June 12 /PRNewswire/ --
Genetic Immunity, a US/Hungarian clinical-stage Company focused on the development of its patented nanomedicines for targeted immune amplification, announced today that the Company will be promoting Hungarian biotech and the country's emerging Nanomedicine leadership position on the international stage at the 2008 Bio International Convention to be held June 17-20, 2008 at the San Diego Convention Center in San Diego, CA.
In support of the Hungarian government's stated goals to concentrate interdisciplinary product-focused Nanomedicine research and development in Hungary, Dr. Julianna Lisziewicz, Genetic Immunity's President and Chief Executive Officer, will present an international case study, "Biotechnology in Hungary: Mission Possible." Dr. Lisziewicz's presentation will take place on Thursday, June 19th at 2:00 p.m. Pacific Time.
The BIO International Convention is the world's largest biotechnology trade conference, attracting more than 20,000 representing over 70 countries. The conference features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. The convention also includes hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition.
Dr. Lisziewicz said, "Hungary is well-positioned to become a European leader in the Nanomedicine space. We have built a sophisticated multidisciplinary Nanomedicine Consortium and have seen tangible success in the form of manufacturing advances and late-stage human clinical trials for Nanomedicines. By promoting our achievements, we are working to attract international experts to collaborate with us in Hungary, creating new jobs for our educated workforce and attracting foreign investment. We are proud of Genetic Immunity's success on the international stage and are excited to leverage it to help support the growth of this knowledge-based industry in Hungary."
For more information on this event please visit: http://www.bio2008.org/
About Genetic Immunity(R)
Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy approved for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific memory T cells.
About the Nanomedicine Technology Platform
Genetic Immunity's nanomedicine immune amplification platform technology is comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can treat a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.
Contacts: The Ruth Group Investors Sara Ephraim +1-646-536-7002 sephraim@theruthgroup.com Media Janine McCargo +1-646-536-7033 jmccargo@theruthgroup.com Web site: http://www.geneticimmunity.com http://www.bio2008.org
Investors, Sara Ephraim, +1-646-536-7002, sephraim@theruthgroup.com, or Media, Janine McCargo, +1-646-536-7033, jmccargo@theruthgroup.com, both of The Ruth Group
Comments